Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders

Medicine & Life Sciences

• Imatinib Mesylate 76%
• abl Genes 40%
• Platelet-Derived Growth Factor beta Receptor 36%
• Mutation 29%
• Pharmaceutical Preparations 27%
• Proto-Oncogene Proteins c-sis 19%
• Proto-Oncogene Proteins c-kit 19%
• Mastocytosis 18%
• Platelet-Derived Growth Factor Receptors 17%
• Myeloproliferative Disorders 17%
• Chromosome Deletion 17%
• Polycythemia Vera 17%
• Primary Myelofibrosis 16%
• Investigational Therapies 16%
• Eosinophilia 14%
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14%
• Hematologic Neoplasms 13%
• Acute Myeloid Leukemia 12%
• Protein-Tyrosine Kinases 12%
• In Vitro Techniques 11%
• Chromosomes 10%
• Genes 5%
• Therapeutics 4%
• Neoplasms 4%

Chemical Compounds

• Imatinib 100%
• Disorder 57%
• Mutation 56%
• Drug 35%
• Drug Target 19%
• Interstitial 17%
• Tyrosine 15%
• Molecule 5%